Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB–IV NSCLC (LCDigital-IO Study): a multicenter retrospective study

BACKGROUND: The predictive efficacy of current biomarker of immune checkpoint inhibitors (ICIs) is not sufficient. This study investigated the causality between radiomic biomarkers and immunotherapy response status in patients with stage IB–IV non-small cell lung cancer (NSCLC), including its biolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Shaowei, Zhan, Weijie, Liu, Lan, Xie, Daipeng, Yao, Lintong, Yao, Henian, Liao, Guoqing, Huang, Luyu, Zhou, Yubo, You, Peimeng, Huang, Zekai, Li, Qiaxuan, Xu, Bin, Wang, Siyun, Wang, Guangyi, Zhang, Dong-Kun, Qiao, Guibin, Chan, Lawrence Wing-Chi, Lanuti, Michael, Zhou, Haiyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603353/
https://www.ncbi.nlm.nih.gov/pubmed/37865396
http://dx.doi.org/10.1136/jitc-2023-007369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603353/
https://www.ncbi.nlm.nih.gov/pubmed/37865396
http://dx.doi.org/10.1136/jitc-2023-007369

Ejemplares similares